Emend Risk Program To Ensure Prescribers Understand Approved Indication
Executive Summary
Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications
You may also be interested in...
Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche
Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS
Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche
Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS
Merck Discontinues Substance P Depression Compound After Failed Trial
Merck is abandoning its efforts to develop the substance P antagonist aprepitant (MK-0869) for treatment of depression